Diagnosis of Hypermobile Ehlers-Danlos Syndrome
Hypermobile Ehlers-Danlos syndrome (hEDS) is diagnosed clinically using the 2017 International Classification criteria, which requires meeting three mandatory criteria: (1) generalized joint hypermobility assessed by the Beighton score, (2) at least two features of a connective tissue disorder, and (3) exclusion of alternative diagnoses through genetic testing and clinical evaluation. 1, 2
The Three-Criterion Diagnostic Framework
Criterion 1: Generalized Joint Hypermobility (Beighton Score)
The Beighton scoring system is the standardized tool for assessing joint hypermobility 1. A positive score requires:
- ≥6/9 points in children before puberty
- ≥5/9 points from puberty to age 50
- ≥4/9 points for those ≥50 years old
The nine-point assessment includes 1:
- Passive dorsiflexion of 5th fingers beyond 90° (1 point each side)
- Passive apposition of thumbs to forearm (1 point each side)
- Elbow hyperextension >10° (1 point each side)
- Knee hyperextension >10° (1 point each side)
- Forward flexion with palms flat on floor with straight knees (1 point)
Criterion 2: Features of Connective Tissue Disorder
At least two of the following must be present 1, 3:
- Systemic manifestations of connective tissue disorder (soft, velvety skin; mild skin hyperextensibility; unexplained striae)
- Positive family history of hEDS in first-degree relative
- Musculoskeletal complications including chronic pain (≥3 months in ≥2 limbs), recurrent joint dislocations/subluxations, or joint instability
Criterion 3: Exclusion of Alternative Diagnoses
This is the most critical and underutilized criterion. 4 You must actively exclude:
- Other EDS subtypes (classical, vascular, kyphoscoliotic)
- Other heritable connective tissue disorders (Marfan syndrome, Loeys-Dietz syndrome, osteogenesis imperfecta)
- Alternative genetic conditions
Genetic testing is essential here - a 2025 study found that 26.4% of patients meeting clinical criteria for hEDS actually had an alternative or additional diagnosis identified through genetic testing, requiring different management strategies 4. This finding fundamentally challenges the notion that hEDS diagnosis is purely clinical.
Critical Diagnostic Pitfalls
The Genetic Testing Controversy
While hEDS has no identified genetic mutation 2, 3, 5, genetic testing remains crucial for excluding other conditions 4, 6. The absence of a genetic marker for hEDS does not mean genetic testing is unnecessary - it means testing is used to rule out the 12 other EDS subtypes and related disorders that DO have identifiable mutations.
Hypermobility Spectrum Disorders (HSD)
Patients with symptomatic joint hypermobility who do not meet full hEDS criteria are classified as having HSD 3, 7. This is not a lesser diagnosis - these patients experience similar symptoms and disability but fall short on one or more of the three criteria. The distinction matters primarily for research classification rather than clinical management, as both groups require similar multidisciplinary approaches.
Associated Conditions to Screen For
Once hEDS is diagnosed, assess for common comorbidities that significantly impact morbidity and quality of life:
Postural Orthostatic Tachycardia Syndrome (POTS)
- Present in 37.5-60% of hEDS patients 1
- Diagnosed by heart rate increase ≥30 bpm within 10 minutes of standing (≥40 bpm in adolescents 12-19 years) without orthostatic hypotension 1
- Do not universally screen all hEDS patients - target testing to those with orthostatic intolerance symptoms 1
Mast Cell Activation Syndrome (MCAS)
- Characterized by multisystem symptoms triggered by foods, temperature changes, mechanical stimuli, or emotional stress 1
- Symptoms must occur in ≥2 body systems (GI, skin, cardiac, neurologic) 1
- Again, targeted testing only - not universal screening 1
Gastrointestinal Manifestations
- 98% of hEDS/HSD patients meet criteria for disorders of gut-brain interaction 1
- Over 60% report at least one GI symptom 1
Practical Diagnostic Algorithm
- Screen with Beighton score - if positive for age, proceed
- Assess for ≥2 connective tissue features - document skin findings, family history, musculoskeletal complications
- Order genetic testing to exclude other EDS subtypes and heritable connective tissue disorders - this is non-negotiable despite hEDS having no known mutation 4
- Clinical evaluation to exclude other hypermobility conditions
- If all three criteria met and alternatives excluded → diagnose hEDS
- If criteria not fully met but symptomatic hypermobility present → diagnose HSD
- Screen for POTS/MCAS only if clinically indicated by symptoms 1
The diagnosis requires clinical expertise and cannot rely on a single test, but the systematic application of these three criteria - particularly the often-neglected third criterion of genetic exclusion - is essential for accurate diagnosis and appropriate management 4, 6.